Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Bjursell, Mikael ^a   Wedin, Marianne ^a   Admyre, Therése ^a   Hermansson, Majlis ^a   Böttcher, Gerhard ^a   Göransson, Melker ^a   Lindén, Daniel ^a   Bamberg, Krister ^a   Oscarsson, Jan ^a   Bohlooly Y, Mohammad ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESOID X RECEPTOR; GLUCOSE; INSULIN;

AGING; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; CALORIC INTAKE; CHOLESTASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENERGY EXPENDITURE; FARNESOID X RECEPTOR GENE; FAT MASS; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; LIVER CELL; LIVER INJURY; LIVER METABOLISM; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; REGULATOR GENE; WEIGHT GAIN; WILD TYPE;

ADIPOSE TISSUE, WHITE; AGING; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; CELL SIZE; ENERGY INTAKE; ENERGY METABOLISM; FATTY LIVER; FEMALE; GLUCOSE; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; ORGAN SIZE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SKIN; TRIGLYCERIDES;

EID: 84877916062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064721     Document Type: Article

References (49)

1. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, et al. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81: 687-693.
2. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, et al. (1999) Bile acids: Natural ligands for an orphan nuclear receptor. Science 284: 1365-1368.
3. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, et al. (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278: 2563-2570.
4. Ma K, Saha PK, Chan L, Moore DD, (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116: 1102-1109.
5. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744.
6. Zhang Y, Ge X, Heemstra LA, Chen WD, Xu J, et al. (2012) Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol Endocrinol 26: 272-280.
7. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, et al. (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281: 11039-11049.
8. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6: 517-526.
9. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, et al. (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48: 2664-2672.
10. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225.
11. Song KH, Li T, Owsley E, Strom S, Chiang JY, (2009) Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49: 297-305.
12. Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, et al. (2003) Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: Efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem 278: 41930-41937.
13. van Dijk TH, Grefhorst A, Oosterveer MH, Bloks VW, Staels B, et al. (2009) An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in fxr-/- mice. J Biol Chem 284: 10315-10323.
14. Zhang Y, Wang X, Vales C, Lee FY, Lee H, et al. (2006) FXR deficiency causes reduced atherosclerosis in ldlr-/- mice. Arterioscler Thromb Vasc Biol 26: 2316-2321.
15. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103: 1006-1011.
16. Yang F, Huang X, Yi T, Yen Y, Moore DD, et al. (2007) Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67: 863-867.
17. Meng Z, Wang Y, Wang L, Jin W, Liu N, et al. (2010) FXR regulates liver repair after CCl4-induced toxic injury. Mol Endocrinol 24: 886-897.
18. Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, et al. (2006) Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312: 233-236.
19. Hashidume T, Sasaki T, Inoue J, Sato R, (2011) Consumption of soy protein isolate reduces hepatic SREBP-1c and lipogenic gene expression in wild-type mice, but not in FXR-deficient mice. Biosci Biotechnol Biochem 75: 1702-1707.
20. Lian F, Xing X, Yuan G, Schafer C, Rauser S, et al. (2011) Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Biochem J 438: 315-323.
21. Dufer M, Horth K, Wagner R, Schittenhelm B, Prowald S, et al. (2012) Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 61: 1479-1489.
22. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, et al. (2011) Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60: 1861-1871.
23. Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, et al. (2010) Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 59: 2916-2927.
24. Kong B, Luyendyk JP, Tawfik O, Guo GL, (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 328: 116-122.
25. Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, et al. (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 328: 469-477.
26. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, et al. (2005) Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 579: 4076-4080.
27. Soriano P, (1999) Generalized lacZ expression with the ROSA26 cre reporter strain. Nat Genet 21: 70-71.
28. Gerdin AK, Surve VV, Jonsson M, Bjursell M, Bjorkman M, et al. (2006) Phenotypic screening of hepatocyte nuclear factor (HNF) 4-gamma receptor knockout mice. Biochemical & Biophysical Research Communications 349: 825-832.
29. Bjursell M, Ahnmark A, Bohlooly YM, William-Olsson L, Rhedin M, et al. (2007) Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56: 583-93.
30. Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, et al. (2011) Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 300: E211-20.
31. Bjursell M, Egecioglu E, Gerdin AK, Svensson L, Oscarsson J, et al. (2005) Importance of melanin-concentrating hormone receptor for the acute effects of ghrelin. Biochemical & Biophysical Research Communications 326: 759-765.
32. Edvardsson U, Ljungberg A, Linden D, William-Olsson L, Peilot-Sjogren H, et al. (2006) PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res 47: 329-340.
33. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL, (2006) Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 285: 35-50.
34. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, et al. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489.
35. Gunawardana SC, Piston DW, (2012) Reversal of type 1 diabetes in mice by brown adipose tissue transplant. Diabetes 61: 674-682.
36. Tang T, Zhang J, Yin J, Staszkiewicz J, Gawronska-Kozak B, et al. (2010) Uncoupling of inflammation and insulin resistance by NF-kappaB in transgenic mice through elevated energy expenditure. J Biol Chem 285: 4637-4644.
37. Binczek E, Jenke B, Holz B, Gunter RH, Thevis M, et al. (2007) Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol Chem 388: 405-418.
38. Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, et al. (1997) Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest 100: 705-712.
39. Moschetta A, Bookout AL, Mangelsdorf DJ, (2004) Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10: 1352-1358.
40. Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, et al. (2004) Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126: 756-764.
41. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, et al. (1998) A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 20: 233-238.
42. Figge A, Lammert F, Paigen B, Henkel A, Matern S, et al. (2004) Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J Biol Chem 279: 2790-2799.
43. Takahashi Y, Soejima Y, Fukusato T, (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18: 2300-2308.
44. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M, (2005) Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 42: 585-591.
45. Inoue M, Tazuma S, Kanno K, Hyogo H, Igarashi K, et al. (2011) Bach1 gene ablation reduces steatohepatitis in mouse MCD diet model. J Clin Biochem Nutr 48: 161-166.
46. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, et al. (2009) CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 119: 1858-1870.
47. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, et al. (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103: 3920-3925.
48. Ye D, Li FY, Lam KS, Li H, Jia W, et al. (2012) Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 61: 1058-1067.
49. Id Boufker H, Lagneaux L, Fayyad-Kazan H, Badran B, Najar M, et al. (2011) Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone 49: 1219-1231.